Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department
Trial Parameters
Brief Summary
Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of back pain. A total of 150 patients age 18-65 presenting to the emergency department with chief complaint of backpain will be enrolled from April 2024 - April 2025. Patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24 hours.
Eligibility Criteria
Inclusion Criteria: * Age 18 - 65 years old * Presenting to the Bronson ED with a chief complaint of acute, non-traumatic back pain * VAS score \>5 cm Exclusion Criteria: * Back pain due to traumatic injury * Experiencing saddle anesthesia * Has bowel or bladder dysfunction * Has an abnormal neurological exam * Requires imaging in ED * Has a Glascow coma score \<15 * Has one or more abnormal vital signs: HR\>120, SBP\>180 or \<90, temperature \>38°, O2 saturation\<92% * Has an allergy to ketorolac or haloperidol * Has a known diagnosis of Lewy Body Dementia * Has a known diagnosis of glaucoma. * Is known to be pregnant or breastfeeding * Is a prisoner or ward of the state * Is unable to consent for themselves/ non-english speaking * In the opinion of the attending physician or investigator the patient should not participate in the research